Both medications have demonstrated significant weight-loss potential, but they work somewhat differently
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinsons disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: the Exenatide-PD3 study
Low-fat versus ketogenic diet in Parkinsons disease: A pilot randomized controlled trial
The combined use of Ang-1/Tie2 agonists with other anti-inflammatory agents, such as IL-1 inhibitors, may produce synergistic effects and further enhance therapeutic outcomes
No eating disorder screen, no pregnancy or breastfeeding screen, no validated PHQ or mental-health instrument, no substance use or alcohol screen, no self-reported blood pressure or resting heart rate , and no MEN-2 gate split out from the personal-or-family MTC question
Reduced physical strain promotes better and more comfortable sleep, which also impacts your energy and mood